Pharmacokinetics of CM 57755, a new histamine H2-receptor antagonist, after single oral doses in man. 1985

J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels

The plasma pharmacokinetics and urinary excretion of CM 57755, an H2-receptor antagonist, were studied after administration of single oral doses in a range between a 100 and 700 mg in human volunteers. Pharmacokinetic parameters were calculated model-independent. Absorption of CM 57755 was bimodal and the maximum plasma concentration was reached between 2 and 4 h after dosing. The drug was widely distributed with an apparent volume of distribution between 140 and 200 l. The plasma clearance was between 56 and 69 L/h. The plasma concentrations declined following a monoexponential function with an elimination half-life of 2 h. No modification in the plasma clearance or other pharmacokinetic parameters with these doses was observed. Therefore, a linear pharmacokinetic profile of CM 57755 was proposed. About 40% of the parent drug was unchanged in urine excreted over the 24 h. The drug was compared with cimetidine and ranitidine, the three compounds seemed to exhibit a consistent pharmacokinetic profile.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009536 Niacinamide An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. Nicotinamide,Vitamin B 3,Vitamin PP,3-Pyridinecarboxamide,Enduramide,Nicobion,Nicotinsäureamid Jenapharm,Papulex,Vitamin B3,3 Pyridinecarboxamide,B 3, Vitamin,B3, Vitamin,Jenapharm, Nicotinsäureamid
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels
January 1983, European journal of clinical pharmacology,
J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels
November 1986, The Journal of pharmacy and pharmacology,
J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels
January 1987, European journal of clinical pharmacology,
J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels
August 1988, Pharmacological research communications,
J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels
December 1975, British journal of clinical pharmacology,
J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels
January 1984, International journal of tissue reactions,
J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels
April 1999, Xenobiotica; the fate of foreign compounds in biological systems,
J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels
July 1989, Arzneimittel-Forschung,
J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels
September 1981, British journal of clinical pharmacology,
J Necciari, and D Mery, and P Garriot, and J Escourrou, and W Cautreels
July 1984, Xenobiotica; the fate of foreign compounds in biological systems,
Copied contents to your clipboard!